ZURICH (Reuters) - Swiss drugmaker Novartis posted worse-than-expected third quarter sales on Thursday, dragged down by the loss of a U.S. patent on its top-selling blood pressure drug Diovan and tough comparisons at its Sandoz unit.
via Reuters: Health News Read More Here..
No comments:
Post a Comment